Market Newsdesk

BOCA RATON, FL, June 10, 2025 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced a strategic partnership with Exponent, a leading Solana-native yield strategy platform. This collaboration will see dfdvSOL, a liquid staking token (LST) adopted by DeFi Dev Corp., integrated into Exponent’s innovative fixed-yield and leverage yield farming vaults.

With this integration, Exponent users can deploy dfdvSOL across three key yield strategies, each tailored to different risk and return preferences:

• Income Vaults – Users can exchange variable yields on dfdvSOL for fixed yield tokens, earning predictable returns at maturity.

• Farm Vaults – Users can gain leveraged exposure to variable yields by purchasing Yield Tokens backed by dfdvSOL at an Implied APY.

• Liquidity Vaults – Users can supply dfdvSOL to Exponent’s Liquidity Vaults, earning extra yield by providing liquidity to yield markets.

“Our integration with Exponent unlocks yet another use case for dfdvSOL and reinforces our north star, driving growth in SOL per share (SPS) for our shareholders,” said Parker White, COO & CIO of DeFi Dev Corp. “Exponent’s yield strategies offer a robust way for users to earn while holding dfdvSOL, enhancing both its demand and the value proposition of our treasury strategy.”

The partnership aligns with DeFi Dev Corp.’s newest initiative centered around enhancing the value proposition of the dfdvSOL LST on Solana and uniquely positioning dfdvSOL within the broader Solana DeFi landscape. dfdvSOL directly ties back to the Company’s validator operations and staking rewards, providing a secure foundation for Exponent users to participate in sophisticated yield strategies.

Disclaimer: DeFi Dev Corp. receives a commission on the SOL rewards generated from its validator operations and a portion of the fee imposed via the Sanctum protocol based on staking operations by dfdvSOL users. DeFi Dev Corp. is not responsible for the development, security, or operation of Sanctum’s technology or infrastructure, and is not acting on behalf of Sanctum. Users should independently evaluate the risks associated with LSTs and related technologies.

About DeFi Development Corp.

DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to Solana (SOL). Through this strategy, the Company provides investors with direct economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged across decentralized finance (DeFi) opportunities and continues to explore innovative ways to support and benefit from Solana’s expanding application layer.

The Company is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions, as well as value-add services, to multifamily and commercial property professionals, as the Company connects the increasingly complex ecosystem that stakeholders have to manage.

The Company currently serves more than one million web users annually, including multifamily and commercial property owners and developers applying for billions of dollars of debt financing per year, professional service providers, and thousands of multifamily and commercial property lenders, including more than 10% of the banks in America, credit unions, real estate investment trusts (“REITs”), debt funds, Fannie Mae® and Freddie Mac® multifamily lenders, FHA multifamily lenders, commercial mortgage-backed securities (“CMBS”) lenders, Small Business Administration (“SBA”) lenders, and more. The Company’s data and software offerings are generally offered on a subscription basis as software as a service (“SaaS”).

About Exponent

Exponent is a yield exchange protocol on Solana for fixed-rate and leveraged yield farming. Users can exchange their productive yield assets (e.g. Jito’s VRTs, lending positions, yield-bearing tokens) for a fixed return or amplified exposure to their yield. Exponent has been built to enable anyone to take directional views on where they expect APYs from DeFi markets to be in the future (e.g. in 1 month, 6 months, 1 year, etc).

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” strategy,” “future,” “likely,” “may,”, “should,” “will” and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations, and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) fluctuations in the market price of SOL and any associated impairment charges that the Company may incur as a result of a decrease in the market price of SOL below the value at which the Company’s SOL are carried on its balance sheet; (ii) volatility in our stock price, including due to future issuances of common stock and securities convertible into common stock; (iii) the effect of and uncertainties related the ongoing volatility in interest rates; (iv) our ability to achieve and maintain profitability in the future; (v) the impact on our business of the regulatory environment and complexities with compliance related to such environment including changes in securities laws or other laws or regulations; (vi) changes in the accounting treatment relating to the Company’s SOL holdings; (vii) our ability to respond to general economic conditions; (vii) our ability to manage our growth effectively and our expectations regarding the development and expansion of our business; (ix) our ability to access sources of capital, including debt financing and other sources of capital to finance operations and growth and (x) other risks and uncertainties more fully in the section captioned “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and other reports we file with the SEC. As a result of these matters, changes in facts, assumptions not being realized, or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact:

[email protected] 

Media Contact:

Prosek Partners
[email protected] 

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) — Operative, the preferred advertising management solution for the world’s leading media companies, today announced that National CineMedia (NASDAQ: NCMI) (“NCM”), the leader in cinema advertising, has partnered with Operative to enhance its advertising operations, improve inventory forecasting, and optimize sales activities across multiple channels. With more than 17,500 screens in over 1,350 theaters across the U.S., NCM’s dynamic cinema advertising platform serves thousands of advertisers at the national, regional, and local level. Through this partnership, Operative will enable NCM to more precisely forecast future demand and help optimize sales and operational workflows to drive improved yield across its business.

“NCM must be at the forefront of technology and innovation in order to deliver targeted advertising at the scale and sophistication our clients have come to expect,” said Catherine Sullivan, President at NCM. “Operative’s suite of solutions will enable us to streamline complex workflows to help our sales and ad operations become more strategic, efficient, and effective for our clients as we take our business to the next level.”

To achieve its goals, NCM will leverage Operative’s suite of solutions including AOS, the cloud-based intelligent media management platform, STAQ, the leading analytics and reporting tool, and OnTarget, an ML-based forecasting tool that delivers incredibly accurate forecasts of future demand for content at the local level. With this insight, NCM can create more accurate packages and proposals for advertisers and deliver more intelligent and effective campaigns that drive better outcomes for clients.

Operative will further enable NCM with:

• Automated and accurate forecasts: ML-based forecasting engine that leverages first-party, third-party, and exogenous data to automate predictions. Forecasts are visible and integrated into the sales process to improve long-term planning, unlock yield optimization, increase revenue generation, and reduce makegoods.
• Sales automation: Streamlined sales portals supporting proposal building, ordering, checkout, creative management, and reporting for clients and sales teams to build healthier pipelines, faster response times, and higher close rates.
• Yield optimization: Programmatic dashboard and executive dashboards to track revenue generation, capture viewership factors, and surface demand forecasts
• Media monetization: SaaS, cloud-based integration hub for the ad sales ecosystem. Cross-platform planning and order management system where planning and yield teams can manage products and plans and maintain deals through their entire lifecycle.

“Through this partnership, Operative will empower NCM with streamlined operations, enhanced forecasting, and integrated inventory to boost revenue, accelerate deal flow, and strengthen their competitive edge in cinema advertising,” said Michael Grossi, CEO at Operative. “In addition to improved sales and ad-ops workflows, NCM will gain unprecedented control over their business with the most accurate forecasting available, enabling precise ad sales and yield management.”

About National CineMedia (NCM)

National CineMedia, Inc. (NCM, NASDAQ:NCMI) is the largest cinema advertising platform in the US. With unparalleled reach and scale, NCM connects brands to sought-after young, diverse audiences through the power of movies and pop culture. A premium video, full-funnel marketing solution for advertisers, NCM enhances marketers’ ability to measure and drive results. NCM’s Noovie^® Show is presented exclusively in 42 leading national and regional theater circuits including the only three national chains, AMC Entertainment Inc. (NYSE:AMC), Cinemark Holdings, Inc. (NYSE:CNK) and Regal Entertainment Group (a subsidiary of Cineworld Group PLC). NCM’s cinema advertising platform consists of more than 17,500 screens in over 1,350 theaters in 184 Designated Market Areas^® (all of the top 50). NCM is the managing member and owner of approximately 100% of National CineMedia, LLC. For more information, visit www.ncm.com.

About Operative

Operative is the preferred advertising management solution provider for over 300 of the world’s top media brands across 18 countries, including Fox, NBCU, Paramount, Disney, Seven Australia and Sky. Operative brings unmatched solutions to manage digital, linear, and converged advertising workflows while connecting, unifying, and activating data across platforms. Since 2000, Operative has grown to process more than $60 billion in advertising revenue. For more information, visit www.operative.com.

Forward-Looking Statements
This press release contains various forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, that reflect management’s current expectations or beliefs regarding, among other things, NCM, Inc.’s ability to forecast future demand and help optimize sales and operations workflows to drive improved yield across its business. Forward-looking statements are subject to a number of important factors, risks, uncertainties and assumptions that could cause actual results to differ materially from those described in any forward-looking statements. Please refer to National CineMedia, Inc.’s (“NCM, Inc.”) Securities and Exchange Commission filings, including the “Risk Factor” section of the NCM Inc.’s Annual Report on Form 10-K for the year ended December 26, 2024 and subsequent Quarterly Reports on Form 10-Q, for further information about risks and uncertainties that could cause actual results to differ materially. Investors are cautioned that reliance on these forward-looking statements involves risks and uncertainties. NCM, Inc. undertakes no obligation to update any forward-looking statement, whether as a result, of new information, future events or otherwise, except as required by law.

Contact:
NCM – [email protected]

Operative – [email protected] 

– Bitcoin treasury as of May 31, 2025 valued at $16.2 million or $3.16 per share

¹

TAMPA, Fla., June 10, 2025 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin mining and technology-based specialty finance company, today announced its preliminary, unaudited Bitcoin mining and operational update for the month ended May 31, 2025.

Metric	Apr 2025		May 2025
– Bitcoin 2
– Mined, net	6.6		6.3
– Sold	(18.0)		–
– Purchased	–		–
– Service Fee	(0.1)		–
– Bitcoin HODL	148.7		155.0
– Machines 2
– Operational	5,121		4,320
– Storage	496		1,297
– Total Machines	5,617		5,617
– Hashrate (EH/s 2 )
– Oklahoma	0.43		0.48
– Hosted	0.13		–
– Energized	0.56		0.48
– Storage	0.05		0.13
– Total	0.61		0.61

“In May, we remained focused on increasing the output of our mining operations in support of our Bitcoin treasury strategy,” said Bruce Rodgers, Chairman and CEO of LM Funding. “Although the number of Bitcoin mined was modestly lower due to the relocation of machines from our hosted Kentucky site to our wholly owned Oklahoma facility, our Bitcoin holdings grew both in volume and value, ending the month at 155 Bitcoin worth over $16 million, or $3.16 per share. We believe the revenue generated from power curtailment activities meaningfully reduces our exposure to both energy and Bitcoin price volatility. This risk-managed approach provides our shareholders with a capital-efficient, Bitcoin-aligned platform that supports our long-term treasury accumulation strategy.”

The reduction in BTC mined is due in part to approximately 800 machines being repositioned from the Core Kentucky site to the Company’s Oklahoma site. Estimated curtailment and energy sales for May 2025 were approximately $70,000.

The Company estimates that the value of its 155 Bitcoin holdings on May 31, 2025, was approximately $16.2 million or $3.16¹ per share, based on a Bitcoin price of approximately $104,600 as of May 31, 2025, compared to a stock share price of $1.93 as of May 30, 2025.

“Our focus remains on capital efficiency and asset optimization,” added Richard Russell, CFO of LM Funding. “The ability to monetize power curtailment while growing our Bitcoin holdings strengthens our balance sheet and supports long-term shareholder value.”

About LM Funding America

LM Funding America, Inc. (Nasdaq: LMFA), operates as a Bitcoin mining and specialty finance company. The company was founded in 2008 and is based in Tampa, Florida. For more information, please visit https://www.lmfunding.com.

Forward-Looking Statements

This press release may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” and “project” and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are not guarantees of future results and conditions but rather are subject to various risks and uncertainties. Some of these risks and uncertainties are identified in the Company’s most recent Annual Report on Form 10-K and its other filings with the SEC, which are available at

www.sec.gov

. These risks and uncertainties include, without limitation, the risks of operating in the cryptocurrency mining business, our limited operating history in the cryptocurrency mining business and our ability to grow that business, the capacity of our Bitcoin mining machines and our related ability to purchase power at reasonable prices, our ability to identify and acquire additional mining sites, the ability to finance our site acquisitions and cryptocurrency mining operations, our ability to acquire new accounts in our specialty finance business at appropriate prices, changes in governmental regulations that affect our ability to collected sufficient amounts on defaulted consumer receivables, changes in the credit or capital markets, changes in interest rates, and negative press regarding the debt collection industry. The occurrence of any of these risks and uncertainties could have a material adverse effect on our business, financial condition, and results of operations.

For investor and media inquiries, please contact:

Investor Relations
Orange Group
Yujia Zhai
[email protected]

¹Bitcoin treasury calculated using 155 Bitcoin held as of 5/31/25 and Bitcoin price of approximately $104,600 as of 5/31/25. Bitcoin per share calculated using 5,133,412 shares outstanding as of 3/31/25 from SEC Form 10-Q filed May 15, 2025
²Unaudited

MELVILLE, N.Y., June 10, 2025 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced today its hiring of Industry leader, Sandy Lipkins, to focus on technology commercialization and business development, effective June 9, 2025. In his role, Mr. Lipkins will be responsible for sourcing, structuring, negotiating and executing strategic alliances and licensing/co-development agreements for BioRestorative domestically and internationally, as well as providing new product and sales expertise to the Company.

Mr. Lipkins has an accomplished record of business development success within the healthcare industry. He brings over 30 years of venture capital, finance, and sales experience, with deep expertise in the anti-aging and wellness sectors. His extensive work and network in stem cells, regenerative medicine, and tissue banking have helped drive the development of a number of cutting-edge therapies. In addition, Mr. Lipkin’s executive experience in scaling, compounding and biologics manufacturing, as well as his proven ability to expand market reach, has been pivotal to company growth. Mr. Lipkins is passionate about promoting anti-aging, healthy lifestyle and bringing cutting-edge regenerative medicine to the critical masses, domestically and internationally. He has taken companies from incubation, to revenue generation and growth, to setting up for sale or other liquidity events.

“We are absolutely thrilled to welcome Sandy to BioRestorative Therapies. Sandy brings a powerful blend of venture capital expertise, entrepreneurial drive, and a deep commitment to the anti-aging and regenerative medicine space. His proven track record in building and scaling companies aligns perfectly with our mission. With his experience and expertise, we see tremendous potential for significant value creation as we advance our clinical pipeline and expand our commercial BioCosmeceuticals platform. I am confident Sandy will play a key role in driving our next phase of growth and innovation,” said Lance Alstodt, Chief Executive Officer of BioRestorative.

Mr. Lipkins stated, “I am excited to join BRTX at such a pivotal time. The Company’s dedication to cutting-edge science in both clinical development and consumer wellness is inspiring, and I see tremendous opportunity to build something truly impactful here. With a strong foundation already in place, I look forward to helping accelerate growth, expand the biocosmeceuticals platform, and bring transformative regenerative solutions to market — both at home in the U.S. and abroad in key international markets.”

About BioRestorative Therapies, Inc.

BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:

• Disc/Spine Program (brtxDISC^™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.

• Metabolic Program (ThermoStem^®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.

• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company’s latest Form 10-K, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:

Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: [email protected]

WESTBROOK, Maine, June 10, 2025 (GLOBE NEWSWIRE) — Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a fast-growing consumer health and wellness company, announced today that Damian Marano has been named Vice President of Beverage, effective immediately. This appointment marks a major milestone in the Company’s aggressive push into the booming functional beverage market.

“We’re excited to welcome Damian to Synergy’s executive leadership team,” said Jack Ross, CEO of Synergy CHC Corp. “Damian’s deep expertise in beverage, CPG, and technology-enabled growth adds another high-caliber industry veteran to further guide our beverage business through its next phase. His proven track record with global brands and high-growth startups aligns perfectly with our strategic priorities, and his leadership will be pivotal as we grow our FOCUSfactor Energy Drink platform and compete in the high-demand better-for-you drinks space.”

Marano brings over 20 years of sales, business development, and executive leadership experience in the beverage and consumer goods industries, most notably at The Coca-Cola Company, where he served in multiple high-impact roles. As Global Director of Sales and Business Development at Coca-Cola, Marano led a $200M ARR portfolio and spearheaded Coca-Cola’s first AI-powered Revenue Growth Management system. He also pioneered the launch of the company’s VOICE AI solution for restaurant partners, enhancing engagement and operational efficiency. Earlier at Coca-Cola, Marano held the role of Vice President of National Sales, where he secured over $2B in annual renewals and helped integrate early-stage digital tools to modernize commercial operations. His data-driven strategies, pricing innovation, and customer-first approach shaped key national initiatives.

In addition to his tenure at Coca-Cola, Marano served as Vice President of Sales Operations at Cypre, where he developed the company’s go-to-market strategy, generating $2.5M in ARR within nine months and achieving three consecutive years of profitability. He also led business development at H2O.ai, delivering a 10x increase in enterprise deal size across CPG and retail clients.

Marano is also the Founder and former General Manager of Docklight Brands, where he built the Marley wellness portfolio from concept to commercialization, scaling the brand to over 25,000 retail locations in 40+ countries and raising capital at an $80M valuation.

Functional Beverage Expansion Is Underway

Synergy’s entry into the functional drinks category is led by the launch of FOCUSfactor Energy Drinks, crafted with fast-acting B-vitamins and nootropics to enhance mental clarity and clean energy. These clean-label beverages align with Synergy’s flagship FOCUSfactor brain-health supplement—available in major retailers such as Costco, Walmart, Amazon, CVS, Walgreens, etc., and other top chains across the U.S., Canada, and the U.K.

“I’m honored to join Synergy at such a transformative time in the Company’s journey,” said Damian Marano, Vice President of Beverage. “The opportunity to build on Synergy’s trusted health brands while helping to advance innovation in the beverage space is incredibly exciting. I look forward to partnering with Jack and the leadership team to unlock long-term value and scale a compelling portfolio of functional beverages.”

Why Investors Should Watch Synergy CHC Corp. (NASDAQ: SNYR):

• Synergy is leveraging FOCUSfactor’s trusted brand equity to meet global demand for cognitive-enhancing and clean-energy drinks.
• Marano brings top-tier expertise in global beverage strategy, retail execution, and brand growth. He joins recently appointed Vice President of Beverage, Erik Shields, with the two working in tandem to scale the Company’s global beverage platform.
• The Company is scaling rapidly across North America, the U.K., and new international markets, creating long-term value potential.

About Synergy CHC Corp.

Synergy CHC Corp. is a provider of consumer health care and lifestyle products. Synergy’s current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested brain health supplement that has been shown to improve memory, concentration and focus, and Flat Tummy, a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their weight management goals.

Investor Relations

Gateway Group

Cody Slach, Greg Robles
949.574.3860
[email protected]

LONGMONT, Colo., June 10, 2025 (GLOBE NEWSWIRE) — Intrado Life & Safety, Inc. (Intrado), the leader in emergency communications technology, and Toyota Connected North America today announced a collaboration to provide Advanced Automatic Collision Notification (AACN) telematics data to public safety answering points (PSAPs) in an i3-compliant format. The data, delivered via AT&T’s nationwide ESInet solution, helps 9-1-1 telecommunicators quickly deploy appropriate emergency response resources based on accident severity.

The technology will be made available through Toyota’s Safety Connect platform on select model year 2026 Toyota and Lexus vehicles in the United States, with more vehicles added in the future.

“AACN technology represents an evolution in how safety professionals coordinate rescue efforts,” said John Snapp, VP of Technology at Intrado. “When a vehicle’s sensors detect a severe collision, telematics data helps 9-1-1 centers by providing vital crash details and a precise location before anyone even calls for help. Emergency response processes are immediately triggered with the right resources, speeding appropriate aid to accident victims when every second counts.”

Intrado’s Emergency Data Broker routes telematics calls to the correct PSAP with location information and other available vehicle data included so that PSAPs can engage first responders sooner. Leveraging a vehicle’s AACN data, such as speed, vehicle orientation, rollover, occupancy count, seatbelt usage, fuel leakage and more, additional details can be sent along with the telematics call in an i3-compliant format and displayed in the telecommunicator’s existing workflow, giving first responders enhanced situational awareness and context.

As an early adopter of Emergency Data Broker, Toyota Connected has been at the forefront of leveraging AACN data, including vehicle color, make, model, fuel type and air bag deployment, to provide helpful information to emergency responders.

“With more than 12.5 million connected Toyota and Lexus vehicles on the road today, we are committed to helping customers during their journeys,” said Kevin O’Dell, Director of Engineering, Toyota Connected North America. “We’re pleased to continue working with Intrado to deliver beneficial AACN data to first responders and further improve emergency response outcomes.”

PSAPs can access Emergency Data Broker information through Intrado’s Spatial Insight and VIPER 7 emergency communication handling and processing solutions – or within other AACN-enabled call handling and public safety systems when delivered via an i3-compliant ESInet, like AT&Ts.

About Intrado

Intrado is the essential partner for those committed to saving lives and protecting communities anywhere in the world. As a leading global provider of trusted emergency response solutions, Intrado improves public safety outcomes by connecting help to those in need. The company blends legacy intelligence, modern technology, and passionately dedicated people to create end-to-end solutions that are innovative, resilient, intuitive, and insightful. For more information, visit www.intrado.com.

About Toyota

Toyota (NYSE:TM) has been a part of the cultural fabric in the U.S. for nearly 70 years, and is committed to advancing sustainable, next-generation mobility through our Toyota and Lexus brands, plus our nearly 1,500 dealerships.

Toyota directly employs nearly 48,000 people in the U.S. who have contributed to the design, engineering, and assembly of more than 35 million cars and trucks at our 11 manufacturing plants. In spring 2025, Toyota’s plant in North Carolina will begin to manufacture automotive batteries for electrified vehicles. With more electrified vehicles on the road than any other automaker, Toyota currently offers 32 electrified options.

Through its Driving Possibilities initiative, the Toyota USA Foundation has committed to creating innovative educational programs within, and in partnership with, historically underserved communities near the company’s U.S. operating sites.

For more information about Toyota, visit www.ToyotaNewsroom.com.

Media Contact

[email protected]

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce that the first commercial benign prostatic hyperplasia (“BPH”) treatment utilizing the TULSA-PRO^® system’s new TULSA-AI^® Volume Reduction Module was successfully conducted yesterday by Naveen Kella, M.D., Founder of The Urology Place and an Adjunct Assistant Professor for the UT Health Science Center San Antonio.

BPH is a non-cancerous enlargement of the prostate gland due to an overgrowth of prostate cells. It is a common condition as men age, often impeding the flow of urine and creating significant lower urinary tract symptoms (“LUTS”). Current BPH treatment with transurethral resection of the prostate (“TURP”) is largely unchanged over the past 100 years. Many alternative treatment methods have been investigated aiming to improve the patient experience and reduce the rates of complications such as bleeding, erectile dysfunction, loss of ejaculation, and the need to stay in the hospital overnight for one, two or more days.

The TULSA procedure, performed using the TULSA-PRO^® system, has the potential to become a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and BPH; to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance and AI-enhanced planning for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine.

Prior to the new TULSA-AI^® Volume Reduction module, the TULSA-PRO^® system was already being used by surgeons world-wide to relieve LUTS in patients with BPH. A few days ago, investigators from the University of Turku and Turku University Hospital in Finland, published a prospective Phase II study demonstrating safe and effective treatment of BPH with TULSA, with clinically marked improvements in urinary function and quality of life while preserving continence and sexual functions. The International Prostate Symptom Score (IPSS) decreased from 17 to 4 (P < 0.001), and IPSS quality of life score improved from 4 to 1 (P < 0.001). The maximum urine flow rate increased from 11.1 to 18.3 mL/s (P < 0.001), and the average flow rate from 4.2 to 9.1 mL/s (P < 0.001). The 26-item Expanded Prostate Cancer Index Composite urinary irritative/obstructive scores improved from 66 to 94 (P < 0.001), and urinary incontinence scores improved from 86 to 100 (P = 0.008). Sexual function remained stable or improved. Of patients using BPH medications prior to TULSA, 96% discontinued it after the procedure. Meanwhile, 100% of patients who were on anti-coagulants did not discontinue their medication before TULSA.

As the name implies, the new TULSA-AI^® Volume Reduction module streamlines TULSA procedures intended to decrease the volume of obstructive prostate tissue in men with LUTS due to BPH. This new software module builds upon the previously cleared TULSA-AI Contouring Assistant to quickly and easily provide personalized treatment plans that avoid peripheral zone ablation, the area physicians want to avoid when treating BPH, as well as the ejaculatory ducts that run inside the prostate. By leveraging state-of-the-art real-time MR imaging data, the software provides the surgeon with choices for ablation volume and duration based on the patients’ unique anatomy, reducing planning complexity and improving consistency across cases. The primary benefit is enhanced procedural efficiency, decreasing total skin-to-skin time to an expected 60-90 minutes and allowing for faster, more personalized care.

Dr. Kella commented, “BPH treatments have advanced at a tremendous pace. Patients and surgeons continue to look for effective treatments that offer minimal complications. We want no bleeding and no hospital stay, but we don’t want to compromise results. TULSA-AI^® Volume Reduction for BPH could be a game-changer in that regard, and it can be completed in 60 to 90 minutes.”

“As demonstrated in the recently published study from the University of Turku, TULSA offers significant improvements in international prostate symptom score, peak urine flow rates, and discontinuation of BPH medications,” said Arun Menawat, Profound’s CEO and Chairman. “That said, while urologists have been treating LUTS using TULSA-PRO^® since we received 510(k) clearance in 2019, and the technology is the only one capable of treating hybrid patients suffering from both prostate cancer and BPH, BPH-only patient volumes have been low due to the relatively longer treatment duration compared to other modalities. TULSA-AI^® Volume Reduction is designed to maintain all of the many proven advantages of treating BPH with TULSA while leveling the playing field on the time it takes for a urologist to plan and complete of the procedure. Accordingly, we believe that TULSA-AI^® will expand our total, truly tangible available market opportunity from 200,000 to 600,000 prostate disease patients per year.”

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO^®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO^® system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO^® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve^®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve^® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve^® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

Forward-Looking Statements

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, any express or implied statements or guidance regarding current or future financial performance; the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment and osteoid osteoma; and the success of Profound’s U.S. commercialization strategy and activities for TULSA-PRO^®. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Profound, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition, statements and projections regarding financial guidance and goals and the attainment of such goals may differ from actual results based on market factors and Profound’s ability to execute its operational and budget plans; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management’s expected ranges. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound’s Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.ca and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

For further information, please contact:

Stephen Kilmer
Investor Relations
[email protected]
T: 647.872.4849

Second White House engagement invitation highlights AgEagle’s leadership role in shaping
critical UAV policy

WICHITA, Kan., June 10, 2025 (GLOBE NEWSWIRE) — AgEagle Aerial Systems Inc. (NYSE: UAVS)(“Company”), a leading provider of unmanned aerial systems (UAS), sensors, and software solutions for commercial and government use, announces the Company participated in a second high-level, invitation only policy discussion with the White House, hosted by the Office of Information and Regulatory Affairs (OIRA). This most recent engagement was centered on the proposed FAA Rule Part 108, which will define the regulatory framework for Beyond Visual Line of Sight (BVLOS) drone operations across the United States. AgEagle CEO Bill Irby joined industry peers from uAvionix, BRINC, Kelly Hills, and Pierce Aerospace in presenting key insights on how enactment of Part 108 will remove significant operational barriers, drive capital investment, and unlock next-generation drone technologies that enhance both commercial and public sector applications.

“This follow-up invitation by OIRA reaffirms the strategic importance of expanding BVLOS operations for the domestic drone industry,” commented Irby. “We were honored to continue our engagement with the White House and contribute our perspective on how thoughtful and timely rulemaking can accelerate innovation, improve safety and compliance, and strengthen the U.S. position as a global leader in drone technology. Of particular value was the discussion of how streamlined regulation will allow broader deployment of autonomous data solutions and open the door for increased economic activity.”

This engagement was made possible in part through the leadership and coordination of the Association for Uncrewed Vehicle Systems International (AUVSI) and the Commercial Drone Alliance (CDA), who played key roles in facilitating industry participation and ensuring productive dialogue between the private sector and federal stakeholders.

The meeting included representatives from 18 leading drone technology companies. Collectively, the discussions included:

• Examples of high-impact technologies that will become viable under the new
• How regulatory clarity will attract increased capital investment into the sector
• The creation of a uniquely American model for drone automation and data services, strengthening domestic capabilities and competitiveness

The finalization of FAA Rule Part 108 is expected to replace the current piecemeal waiver-based system, providing a more predictable, scalable, and innovation-friendly regulatory environment. AgEagle sees this as a pivotal moment for enabling widespread commercial drone adoption across agriculture, energy, construction, emergency response, and government services.

About AgEagle Aerial Systems Inc.

Through its three Centers of Excellence, AgEagle is actively engaged in designing and delivering best-in-class flight hardware, sensors and software that solve important problems for its customers. Founded in 2010, AgEagle was originally formed to pioneer proprietary, professional-grade, fixed-winged drones and aerial imagery-based data collection and analytics solutions for the agriculture industry. Today, AgEagle is a leading provider of full stack UAS, sensors and software solutions for customers worldwide in the energy, construction, agriculture, and government verticals. For additional information, please visit our website at www.ageagle.com.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on AgEagle’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future purchase orders relating to AgEagle’s products, the success of new programs and software updates, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of AgEagle in general, see the risk disclosures in the Annual Report on Form 10-K of AgEagle for the year ended December 31, 2024, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by AgEagle. All such forward-looking statements speak only as of the date they are made, and AgEagle undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.

Media Contact

Andy Woodward
+1 (469) 451-2344
[email protected]

LinkedIn

 

Facebook

 

X

 

YouTube

Investor Relations

Email: [email protected]

DENVER, June 10, 2025 (GLOBE NEWSWIRE) — GrowGeneration Corp. (NASDAQ: GRWG) (“GrowGen” or the “Company”), the nation’s largest specialty retailer of hydroponic and organic gardening products, today announced it has entered into a distribution agreement with V1 Solutions, a Macedonia-based company that will act as GrowGen’s sales and marketing partner for its proprietary product lines throughout the European Union. Additionally, the Company announced the distribution of its proprietary products in Costa Rica, making its products available to cultivators in Central America.

Targeted EU Expansion Driven by Evolving Cannabis Landscape

V1 Solutions has developed and maintains key strategic relationships with commercial cultivators across the European region. This agreement enables GrowGen to meet the growing demand for advanced cultivation products that comply with evolving regulatory and quality standards as cannabis reform accelerates across the European Union.

Target markets include:

• Germany, where recreational cannabis was legalized in 2024, unlocking significant commercial and medical cultivation potential.
• Portugal, a leading exporter of medical cannabis to the EU and a hub for EU-GMP-certified cultivation.
• Malta and Luxembourg, which have enacted progressive cannabis reform and are scaling their domestic cultivation industries.
• The Netherlands, launching pilot adult-use programs with government-licensed growers.
• Czech Republic and Greece, where updated regulatory frameworks are attracting major cultivation investments.
• Macedonia, as a strategic Balkan hub supporting EU-facing cannabis production.
• Uruguay, a pioneer in cannabis legalization, opening doors for broader South American market expansion.

GrowGeneration will supply commercial cultivators, garden centers, and licensed operators in these countries with its proprietary brands—Drip Hydro, Char Coir, Ion Lighting, Power Si, and The Harvest Company—designed by growers for growers.

Costa Rica: Gateway to Central American Expansion

GrowGen has also launched its proprietary brands in Costa Rica, whose government has issued over 50 licenses for hemp and cannabis production during the past year. The country’s favorable growing conditions and developing export infrastructure make it a key growth market in Central America.

“As legalization advances, the EU and Costa Rica are rapidly becoming some of the most promising cannabis cultivation markets in the world,” said Darren Lampert, GrowGen’s Co-Founder and Chief Executive Officer. “We are thrilled to bring our proven product lines to professional growers across Europe and Central America, who are seeking yield-maximizing, cost-effective solutions backed by North American cultivation expertise.”

International Expansion Strategy

GrowGen is actively exploring additional markets in Eastern Europe and Latin America, consistent with its strategy to serve high-growth regions through local partnerships and product education. GrowGeneration’s international expansion activities align with its. The Company’s international sales infrastructure, regulatory expertise, and strong distribution network position it to capitalize on the cannabis cultivation boom in regions where legalization continues to advance.

About GrowGeneration Corp:

GrowGen is the nation’s largest specialty hydroponic and organic gardening retailer. GrowGen carries and sells thousands of products, such as nutrients, additives, growing media, lighting, environmental control systems, and benching and racking, including proprietary brands such as Charcoir, Drip Hydro, Power Si, Ion lights, The Harvest Company, and more. The Company also operates an online superstore for cultivators at growgeneration.com, as well as a wholesale business for resellers, and a benching, racking, and storage solutions business, Mobile Media or MMI.

To be added to the GrowGeneration email distribution list, please email [email protected] with GRWG in the subject line.

Forward Looking Statements:

This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws. While these forward-looking statements represent current judgments, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect opinions only as of the date of this release. Please keep in mind that the Company does not have an obligation to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. When used herein, words such as “look forward,” “expect,” “believe,” “anticipate,” “estimate,” or variations of such words and similar expressions are intended to identify forward-looking statements. Factors that could cause actual results to differ materially from those contemplated in any forward-looking statements made by us herein are often discussed in filings made with the United States Securities and Exchange Commission, available at: www.sec.gov, and on the Company’s website, at: www.growgeneration.com.

Contacts:

KCSA Strategic Communications
Philip Carlson
Managing Director
T: 212-896-1233
E: [email protected]

IRVING, Texas, June 10, 2025 (GLOBE NEWSWIRE) — Sow Good Inc. (Nasdaq: SOWG) (“Sow Good” or “the Company”), a trailblazer in the freeze dried candy and treat industry, today announced the appointment of Donna Guy, CPA, as Chief Financial Officer, effective June 5, 2025. Ms. Guy succeeds Brendan Fischer, who served as Interim CFO since April 2024.

Ms. Guy brings over 25 years of experience in financial leadership across public and private companies. Most recently, she served as Principal Consultant and founder of Elevation Accounting & Finance, LLC, where since 2021 she has advised organizations on accounting operations, SEC reporting, system implementations, and process optimization. Notably, Ms. Guy previously consulted with Sow Good Inc. on accounting and reporting requirements, giving her a deep understanding of the company’s operations and strategic goals.

Prior to founding Elevation, Ms. Guy served as Controller and later Interim Chief Financial Officer at ADDvantage Technologies Group, Inc. (2020–2021), and as Senior Director of Financial Planning & Analysis at Basic Energy Services (2016–2020). Earlier in her career, she held senior roles in SEC reporting and accounting at Enduro Resource Partners, XTO Energy, and other leading firms. Ms. Guy began her career as an auditor after earning her Bachelor of Business and Accounting from the University of Texas at Arlington in 1998.

“We are excited to welcome Donna to the executive leadership team,” said Claudia Goldfarb, CEO of Sow Good Inc. “Her extensive background in corporate finance, public company reporting, and operational leadership—combined with her prior advisory work with Sow Good—positions her uniquely to help drive our continued growth and financial performance.”

Ms. Guy is a licensed CPA and an active member of the AICPA, the Texas Society of CPAs, and COPAS. She is also a U.S. Air Force veteran and previously served on the board of the Women’s Center of Tarrant County for six years.

Commenting on her appointment, Ms. Guy stated: “I’m thrilled to formally join Sow Good at such an exciting time in the company’s journey. Having already worked closely with the team in a consultative capacity, I’m well-positioned to hit the ground running and contribute immediately to our strategic and financial goals.”

Brendan Fischer will assist in the transition process to ensure a seamless handover of responsibilities. 

About Sow Good Inc.

Sow Good Inc. is a trailblazing U.S.-based freeze dried candy and snack manufacturer dedicated to providing consumers with innovative and explosively flavorful freeze dried treats. Sow Good has harnessed the power of our proprietary freeze-drying technology and product-specialized manufacturing facility to transform traditional candy into a novel and exciting everyday confectionaries subcategory that we call freeze dried candy. Sow Good is dedicated to building a company that creates good experiences for our customers and growth for our investors and employees through our core pillars: (i) innovation; (ii) scalability; (iii) manufacturing excellence; (iv) meaningful employment opportunities; and (v) food quality standards.

Sow Good Investor Inquiries:

Cody Slach
Gateway Group, Inc.
1-949-574-3860
[email protected]  

Sow Good Media Inquiries:

Sow Good, Inc.
1-214-623-6055
[email protected]